Analysis and reporting of adverse events in randomised controlled trials: a review
Analysis and reporting of adverse events in randomised controlled trials: a review
OBJECTIVE: To ascertain contemporary approaches to the collection, reporting and analysis of adverse events (AEs) in randomised controlled trials (RCTs) with a primary efficacy outcome.
DESIGN: A review of clinical trials of drug interventions from four high impact medical journals.
DATA SOURCES: Electronic contents table of the BMJ, the Journal of the American Medical Association (JAMA), the Lancet and the New England Journal of Medicine (NEJM) were searched for reports of original RCTs published between September 2015 and September 2016.
METHODS: A prepiloted checklist was used and single data extraction was performed by three reviewers with independent check of a randomly sampled subset to verify quality. We extracted data on collection methods, assessment of severity and causality, reporting criteria, analysis methods and presentation of AE data.
RESULTS: We identified 184 eligible reports (BMJ n=3; JAMA n=38, Lancet n=62 and NEJM n=81). Sixty-two per cent reported some form of spontaneous AE collection but only 29% included details of specific prompts used to ascertain AE data. Numbers that withdrew from the trial were well reported (80%), however only 35% of these reported whether withdrawals were due to AEs. Results presented and analysis performed was predominantly on 'patients with at least one event' with 84% of studies ignoring repeated events. Despite a lack of power to undertake formal hypothesis testing, 47% performed such tests for binary outcomes.
CONCLUSIONS: This review highlighted that the collection, reporting and analysis of AE data in clinical trials is inconsistent and RCTs as a source of safety data are underused. Areas to improve include reducing information loss when analysing at patient level and inappropriate practice of underpowered multiple hypothesis testing. Implementation of standard reporting practices could enable a more accurate synthesis of safety data and development of guidance for statistical methodology to assess causality of AEs could facilitate better statistical practice.
adverse drug reactions, adverse events, harm data, investigational drug, randomised controlled trials, systematic review
Phillips, Rachel
97860f3f-56e6-4b7b-a4e4-b1ab1fc539a1
Hazell, Lorna
1c9036d8-13c0-4fe1-88be-9a926dc003b5
Sauzet, Odile
a3752468-54b7-4f35-b00c-66c6333caefb
Cornelius, Victoria
b75c21d7-2c25-495c-9107-e39453a72bdd
2019
Phillips, Rachel
97860f3f-56e6-4b7b-a4e4-b1ab1fc539a1
Hazell, Lorna
1c9036d8-13c0-4fe1-88be-9a926dc003b5
Sauzet, Odile
a3752468-54b7-4f35-b00c-66c6333caefb
Cornelius, Victoria
b75c21d7-2c25-495c-9107-e39453a72bdd
Phillips, Rachel, Hazell, Lorna, Sauzet, Odile and Cornelius, Victoria
(2019)
Analysis and reporting of adverse events in randomised controlled trials: a review.
BMJ Open, 9 (2), [e024537].
(doi:10.1136/bmjopen-2018-024537).
Abstract
OBJECTIVE: To ascertain contemporary approaches to the collection, reporting and analysis of adverse events (AEs) in randomised controlled trials (RCTs) with a primary efficacy outcome.
DESIGN: A review of clinical trials of drug interventions from four high impact medical journals.
DATA SOURCES: Electronic contents table of the BMJ, the Journal of the American Medical Association (JAMA), the Lancet and the New England Journal of Medicine (NEJM) were searched for reports of original RCTs published between September 2015 and September 2016.
METHODS: A prepiloted checklist was used and single data extraction was performed by three reviewers with independent check of a randomly sampled subset to verify quality. We extracted data on collection methods, assessment of severity and causality, reporting criteria, analysis methods and presentation of AE data.
RESULTS: We identified 184 eligible reports (BMJ n=3; JAMA n=38, Lancet n=62 and NEJM n=81). Sixty-two per cent reported some form of spontaneous AE collection but only 29% included details of specific prompts used to ascertain AE data. Numbers that withdrew from the trial were well reported (80%), however only 35% of these reported whether withdrawals were due to AEs. Results presented and analysis performed was predominantly on 'patients with at least one event' with 84% of studies ignoring repeated events. Despite a lack of power to undertake formal hypothesis testing, 47% performed such tests for binary outcomes.
CONCLUSIONS: This review highlighted that the collection, reporting and analysis of AE data in clinical trials is inconsistent and RCTs as a source of safety data are underused. Areas to improve include reducing information loss when analysing at patient level and inappropriate practice of underpowered multiple hypothesis testing. Implementation of standard reporting practices could enable a more accurate synthesis of safety data and development of guidance for statistical methodology to assess causality of AEs could facilitate better statistical practice.
Text
e024537.full
- Version of Record
More information
Accepted/In Press date: 16 January 2019
e-pub ahead of print date: 1 March 2019
Published date: 2019
Keywords:
adverse drug reactions, adverse events, harm data, investigational drug, randomised controlled trials, systematic review
Identifiers
Local EPrints ID: 439117
URI: http://eprints.soton.ac.uk/id/eprint/439117
ISSN: 2044-6055
PURE UUID: 7d7ae939-67e3-4b21-9974-f001af03f99f
Catalogue record
Date deposited: 03 Apr 2020 16:31
Last modified: 05 Jun 2024 18:47
Export record
Altmetrics
Contributors
Author:
Rachel Phillips
Author:
Odile Sauzet
Author:
Victoria Cornelius
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics